Galcanezumab shows sustained efficacy, CV safety in migraine
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
Galcanezumab shows sustained efficacy, CV safety in migraine
05 May 2021